American Journal of Interdisciplinary Research and Development
ISSN Online: 2771-8948
Website: www.ajird.journalspark.org
Volume 17, June, 2023

ROLE OF MICRORNAS IN THE EARLY DIAGNOSIS OF NAFLD/FIBROSIS

Parpibayeva Dinara Ayupovna1
Ergashov Nodirbek Shermuxamat o‘g‘li1
Boltaboyev Xikmat Qudrat o‘g‘li1
Tojiboyev Mirkomil Sayduvali o'g'li1
Namozova Gulasal Qosim qizi1
1Tashkent Medical Academy

Abstract
Nonalcoholic fatty liver disease (NAFLD) and fibrosis are two of the most common liver diseases worldwide, with a rising incidence due to the increasing prevalence of obesity and metabolic syndrome. Early diagnosis and treatment are essential to prevent the progression of these conditions to more severe liver diseases. MicroRNAs (miRNAs) are small non-coding RNAs that play a crucial role in the regulation of gene expression and have emerged as promising biomarkers for the early diagnosis and monitoring of NAFLD and fibrosis. This review article provides an overview of the role of miRNAs in the pathogenesis of NAFLD and fibrosis, the potential of miRNAs as biomarkers and therapeutic targets for these conditions, and the current state of research in this field. The article also discusses the primary risk factors for NAFLD and fibrosis and the stages of these conditions that can be identified through the use of non-invasive imaging techniques and serum biomarkers, including miRNAs. Finally, the article provides recommendations for future research and the implications for clinical practice, highlighting the potential of miRNAs for improving the early diagnosis and treatment of NAFLD and fibrosis.

INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) is a common condition that affects millions of people worldwide. It is characterized by the accumulation of fat in the liver, which can lead to inflammation, fibrosis, and other complications over time. Early diagnosis of NAFLD and its progression to fibrosis is crucial for effective treatment and management, but current diagnostic methods are limited. MicroRNAs (miRNAs) are small non-coding RNAs that play a crucial role in the regulation of gene expression and have been implicated in the pathogenesis of NAFLD and fibrosis. In recent years, there has been growing interest in the potential use of miRNAs as biomarkers for the early diagnosis of NAFLD and fibrosis. MicroRNAs (miRNAs) are small non-coding RNA molecules that play a key role in the regulation of gene expression. They are involved in a wide range of cellular processes, including development, differentiation, proliferation, and apoptosis. MiRNAs function by

binding to messenger RNA (mRNA) molecules and inhibiting their translation into proteins, thereby regulating the expression of specific genes.

In recent years, miRNAs have emerged as promising biomarkers for the diagnosis and prognosis of a variety of diseases, including cancer, cardiovascular disease, and liver disease. In particular, miRNAs have been implicated in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and fibrosis, two conditions that are becoming increasingly prevalent worldwide. NAFLD is characterized by the accumulation of fat in the liver, while fibrosis involves the progressive scarring of liver tissue.

The purpose of this article is to provide an overview of the role of miRNAs in the early diagnosis of NAFLD and fibrosis. We will discuss the mechanisms by which miRNAs regulate gene expression, their potential as biomarkers for NAFLD and fibrosis, and the current state of research in this field. We will also explore the challenges and opportunities associated with the use of miRNAs as diagnostic tools for these conditions. Ultimately, our goal is to provide insights into the potential of miRNAs to improve the diagnosis and treatment of NAFLD and fibrosis, and to stimulate further research in this area.

RISK FACTORS AND ETIOLOGY OF NAFLD AND FIBROSIS

NAFLD is a complex condition that can develop as a result of a variety of factors. The primary risk factors for NAFLD include obesity, insulin resistance, type 2 diabetes, and metabolic syndrome. Other risk factors may include high blood pressure, high cholesterol, and a diet high in saturated and trans fats. Genetics may also play a role in the development of NAFLD.

The exact etiology of NAFLD is not fully understood, but it is believed to involve a combination of genetic, environmental, and lifestyle factors. In particular, insulin resistance and inflammation are thought to play a key role in the development of NAFLD. Insulin resistance can lead to the accumulation of fat in the liver, while inflammation can cause damage to liver cells and promote the development of fibrosis.

Fibrosis is a progressive scarring of liver tissue that can develop as a result of chronic liver damage. In the context of NAFLD, fibrosis can occur as a result of inflammation and damage to liver cells. The severity of fibrosis can range from mild to severe, and can eventually lead to cirrhosis and liver failure if left untreated.

STAGES OF NAFLD AND FIBROSIS

NAFLD is typically divided into four stages based on the degree of liver damage and the presence of inflammation and fibrosis. These stages include:

- Stage 1: Simple fatty liver, characterized by the accumulation of fat in the liver
- Stage 2: Non-alcoholic steatohepatitis (NASH), characterized by inflammation and damage to liver cells
- Stage 3: Fibrosis, characterized by the development of scar tissue in the liver
- Stage 4: Cirrhosis, characterized by severe scarring of liver tissue and impaired liver function

Fibrosis is also typically divided into four stages, based on the degree of scarring and liver damage. These stages include:

- Stage 1: Mild fibrosis, characterized by the development of fibrous tissue in the liver
- Stage 2: Moderate fibrosis, characterized by the development of more extensive fibrous tissue in the liver
- Stage 3: Severe fibrosis, characterized by the development of bridging fibrosis between different lobes of the liver
- Stage 4: Cirrhosis, characterized by the development of extensive scarring and impaired liver function

Understanding the risk factors, etiology, and stages of NAFLD and fibrosis is crucial for effective diagnosis and treatment of these conditions. By identifying the underlying causes of liver damage and inflammation, healthcare providers can develop targeted treatment plans that address the specific needs of each patient.

Non-alcoholic fatty liver disease (NAFLD) and fibrosis are complex conditions that involve a variety of molecular mechanisms. The development and progression of NAFLD is thought to be driven by a combination of genetic and environmental factors, such as a high-fat diet, sedentary lifestyle, and insulin resistance.

MOLECULAR MECHANISMS INVOLVED IN THE DEVELOPMENT AND PROGRESSION OF NAFLD AND FIBROSIS

One key molecular mechanism involved in the development of NAFLD is lipid metabolism. In individuals with NAFLD, there is an accumulation of triglycerides in the liver, which can lead to the formation of lipid droplets and subsequent inflammation and fibrosis. This process is thought to be mediated by a variety of transcription factors, including sterol regulatory element-binding protein 1c (SREBP-1c) and peroxisome proliferator-activated receptor alpha (PPARα).

Another important molecular mechanism involved in the development of NAFLD is oxidative stress. In individuals with NAFLD, there is an imbalance between the production of reactive oxygen species (ROS) and the body's ability to neutralize them. This can lead to damage to cellular components, including DNA, proteins, and lipids, and subsequent inflammation and fibrosis. This process is thought to be mediated by a variety of factors, including nuclear factor kappa B (NF-κB) and mitogen-activated protein kinases (MAPKs).

In addition to these molecular mechanisms, there is growing evidence that microRNAs (miRNAs) play a role in the development and progression of NAFLD and fibrosis. miRNAs are small non-coding RNAs that post-transcriptionally regulate gene expression by binding to target mRNAs. Several miRNAs have been implicated in the regulation of lipid metabolism, oxidative stress, and inflammation in the liver, and are therefore potential biomarkers and therapeutic targets for NAFLD and fibrosis.

The molecular mechanisms involved in the development and progression of NAFLD and fibrosis are complex and multifaceted. A better understanding of these mechanisms is

critical for the development of effective diagnostic and therapeutic strategies for these conditions.

MICRORNAS AS BIOMARKERS FOR EARLY DIAGNOSIS OF NAFLD/FIBROSIS

Biomarkers play an important role in the early diagnosis and management of NAFLD/Fibrosis. Currently, the most widely used biomarkers for NAFLD/Fibrosis are liver enzymes, such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and imaging techniques, such as ultrasound, computed tomography (CT) scan, and magnetic resonance imaging (MRI). However, these biomarkers have limitations in terms of sensitivity and specificity, particularly in the early stages of the disease.

MicroRNAs (miRNAs) have emerged as a promising class of biomarkers for the early diagnosis of NAFLD/Fibrosis. miRNAs are small non-coding RNAs that regulate gene expression post-transcriptionally by binding to target mRNAs. They are stable in body fluids, such as blood, urine, and saliva, and can be easily measured using quantitative polymerase chain reaction (qPCR) or next-generation sequencing (NGS) techniques.

Several miRNAs have been identified as potential biomarkers for NAFLD/Fibrosis based on their involvement in the molecular mechanisms underlying the disease, including lipid metabolism, oxidative stress, and inflammation. For example, miR-122, which is predominantly expressed in the liver, has been shown to be downregulated in NAFLD/Fibrosis and may serve as a biomarker for the disease. Other miRNAs, such as miR-34a, miR-21, and miR-27a, have also been implicated in the pathogenesis of NAFLD/Fibrosis and may serve as potential biomarkers.

The use of miRNAs as biomarkers for NAFLD/Fibrosis has several advantages over traditional biomarkers. First, miRNAs are highly specific to the disease and can detect early stages of NAFLD/Fibrosis. Second, miRNAs are stable in body fluids and can be easily measured using qPCR or NGS techniques. Third, miRNAs can be used to monitor disease progression and response to therapy.

However, there are also some limitations to the use of miRNAs as biomarkers for NAFLD/Fibrosis. First, miRNAs are subject to variability due to factors such as age, sex, and comorbidities. Second, the sensitivity and specificity of miRNA biomarkers may vary depending on the sample type and the method of detection. Third, the validation of miRNA biomarkers requires large-scale, multi-center studies.

Despite these limitations, there is growing evidence to support the potential of miRNAs as biomarkers for NAFLD/Fibrosis. Several studies have reported high diagnostic accuracy for miRNA biomarkers in NAFLD/Fibrosis, with sensitivity and specificity ranging from 80-90%. Additionally, miRNA biomarkers have been shown to be useful for predicting disease progression and response to therapy.

CONCLUSION

In conclusion, microRNAs have emerged as promising biomarkers and therapeutic targets for the early diagnosis and treatment of NAFLD and fibrosis. The primary risk factors for NAFLD, including obesity, insulin resistance, type 2 diabetes, and metabolic syndrome, can lead to the dysregulation of microRNAs involved in lipid metabolism and inflammation. The stages of NAFLD and fibrosis can be identified through the use of non-invasive imaging techniques and serum biomarkers, including microRNAs.

Research has shown that microRNAs have the potential to serve as biomarkers for the early diagnosis of NAFLD and fibrosis and may also be useful as therapeutic targets for the development of new treatments. The development of miRNA-based therapies for NAFLD and fibrosis is an exciting area of research that holds great promise for the future.

The implications for clinical practice are significant, as the early diagnosis and treatment of NAFLD and fibrosis can help prevent the progression of these conditions to more severe liver diseases. Healthcare providers can use serum biomarkers, including microRNAs, to identify patients at risk for NAFLD and fibrosis and monitor disease progression.

Future research should focus on further elucidating the mechanisms by which microRNAs contribute to the pathogenesis of NAFLD and fibrosis and the development of miRNA-based therapies for these conditions. Additionally, large-scale clinical trials are needed to validate the utility of miRNA biomarkers for the early diagnosis and monitoring of NAFLD and fibrosis.

In summary, microRNAs have significant potential as biomarkers and therapeutic targets for the early diagnosis and treatment of NAFLD and fibrosis. The development of miRNA-based therapies has the potential to revolutionize the treatment of these conditions and improve patient outcomes. Healthcare providers should consider the use of miRNA biomarkers in the diagnosis and monitoring of NAFLD and fibrosis, and future research should focus on further elucidating the role of microRNAs in the pathogenesis of these conditions and the development of new treatments.

References

1. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016 Apr;65(4): 1038-1048. doi: 10.1016/j.metabol.2015.12.012. Epub 2016 Jan 11. PMID: 27085771.

2. Golabi P, Otgonsuren M, de Avila L, Sayiner M, Rafiq N, Younossi ZM. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine (Baltimore). 2018 Jan;97(2):e0214. doi: 10.1097/MD.0000000000000214. PMID: 29384899; PMCID: PMC5795412.

3. Povero D, Feldstein AE. Novel molecular mechanisms in the development of non-alcoholic steatohepatitis. Diabetes Metab J. 2016 Feb;40(1):1-11. doi: 10.4093/dmj.2016.40.1.1. Epub 2016 Feb 17. PMID: 26989315; PMCID: PMC4778569.

4. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010 Apr;53(4):372-84. doi: 10.1016/j.jhep.2010.04.008. PMID: 20546736.
5. Tacke F, Weiskirchen R. An update on the pathogenesis of liver fibrosis. Expert Rev Gastroenterol Hepatol. 2012 Jun;6(3): 343-357. doi: 10.1586/egh.12.22. PMID: 22690661.
6. Wang X, Sundquist K, Svensson PJ, Sundquist J, Memon AA. Association of nonalcoholic fatty liver disease with thrombosis-related factors and decreased kidney function in a Swedish population-based cohort. Metabolism. 2019 Feb;91: 37-44. doi: 10.1016/j.metabol.2018.10.010. Epub 2018 Oct 26. PMID: 30367912.
7. Yilmaz Y. Systematic review: Nonalcoholic steatohepatitis - a global epidemic and a ticking time-bomb. Aliment Pharmacol Ther. 2015 Oct;42(8): 993-1000. doi: 10.1111/apt.13323. Epub 2015 Aug 27. PMID: 26310769.
8. Parpibaeva, D. A., Sh, E. N., Musaeva, M. A., Boltaboev, X. K., & Turbanova, U. V. (2023). SIMULATION TRAINING IN MEDICINE: FROM PROBLEM TO SOLUTION.
9. Ayupovna, P. D. (2023). EVALUATION OF THE EFFECTIVENESS OF SIMULATION TRAINING IN TEACHING HEART AND LUNG AUSCULTATION.
10. Najmutdinova, D. Q., Parpibaeva, D. A., Salaeva, M. S., Salimova, N. D., Ergashov, N. S., & Sultonova, D. A. (2023). The role of fenofibrate (tricor) in the complex treatment of microangiopathic complications in patients with type 2 diabetes.
11. Parpibayeva, D. A., Salimova, N. D., Ergashov, N., Baltabayev, H. Q., & Sultanova, M. X. (2022). Tibbiyotda simulyatsion o'qitish: muammodan yechimgacha.
12. Parpibaeva, D. A., Saidobdullaevna, S. M., & Djurabaevna, S. N. (2022). MICRONA-122: PROGRESSION TO THE STAGE OF SEVERE FIBROSIS.